AKT1 and cancer: All compounds showed better activity against STAT3, P13 Kalpha and Human A. c-Kit Tyrosine Kinase and Protein Kinase B (Akt) were predicted to have a strong interaction potential against the cancer therapeutic targets with the best binding poses and a low binding energy.